Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Fahed Bitar

Interventional Cardiology Covina, CA Medical Doctor

NPI 1174728612 CMS profile 325557

315 N. Third Ave., Suite 207, Covina, CA 91723

Open in the dashboard

General payments

$41,143

962 records reported · program years 2019–2025

Research payments

$230,951

Paid to them · 19 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$9,816,305 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Fahed Bitar of Covina, CA is reported in the CMS Open Payments database as having received $41,143 across 962 general payments and $230,951 in research payments paid to them. Separately, studies naming them as principal investigator received $9,816,305 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 97th percentile of Interventional Cardiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

13 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,077 127
2024 General $2,543 115
2024 Research $88,784 8
2023 General $2,631 122
2023 Research $1,782 4
2022 General $2,318 117
2022 Research $146 2
2021 General $6,508 180
2021 Research $117,186 2
2020 General $5,886 114
2020 Research $197 1
2019 General $18,180 187
2019 Research $22,856 2

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Fahed Bitar
  • Interventional Cardiology median
  • Middle half of Interventional Cardiology
  • National median

In program year 2025, general payments to Fahed Bitar were reported at $3,077. Among 6,173 Interventional Cardiology profiles paid that year, the median was $1,092 and the middle half received between $366 and $3,019.

Show as a table
Year Fahed Bitar Interventional Cardiology median Middle half National median
2019 $18,180 $1,097 $329–$3,048 $163
2020 $5,886 $473 $161–$1,480 $114
2021 $6,508 $677 $233–$1,827 $132
2022 $2,318 $978 $333–$2,724 $149
2023 $2,631 $1,136 $382–$2,986 $160
2024 $2,543 $1,181 $395–$3,326 $164
2025 $3,077 $1,092 $366–$3,019 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. E.R. Squibb & Sons, L.L.C. $12,065 44 payments
  2. Novartis Pharmaceuticals Corporation $7,983 191 payments
  3. AstraZeneca Pharmaceuticals LP $3,285 31 payments
  4. Abbott Laboratories $2,826 58 payments
  5. Abiomed $2,120 81 payments
  6. Edwards Lifesciences Corporation $1,544 31 payments
  7. Pfizer Inc. $1,512 87 payments
  8. Boston Scientific Corporation $1,322 54 payments
  9. Medtronic, Inc. $1,076 36 payments
  10. Amgen Inc. $791 41 payments
  11. Other $6,618 308 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $21,620 934 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $18,400 9 payments
  3. Consulting Fee $750 2 payments
  4. Education $373 17 payments
Products named General payments · program years 2019–2025
  1. ELIQUIS Cardiovascular $11,896 41 payments
  2. ENTRESTO $6,757 109 payments
  3. FARXIGA $3,018 20 payments
  4. Impella $2,082 80 payments
  5. ELIQUIS Cardiovascular;Metabolic Disease $1,224 71 payments
  6. LEQVIO $826 62 payments
  7. Xience Sierra Coronary Stent System $754 7 payments
  8. Repatha $753 39 payments
  9. SAPIEN 3 Ultra RESILIA $708 15 payments
  10. LifeVest $629 50 payments
  11. Other $13,916 551 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Eli Lilly and Company $230,732 17 payments
  2. Abiomed $219 2 payments

Prescribing to Medicare patients

Part D · data year 2024 · 52 drugs

Part D claims

5,084

Median for Interventional Cardiology: 2,236

Drug cost

$902,453

Median for Interventional Cardiology: $380,412

Branded share of claims

29.1%

Median for Interventional Cardiology: 27.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 381 $403,824
Entresto Sacubitril/Valsartan Brand 183 $168,433
Xarelto Rivaroxaban Brand 94 $95,388
Jardiance Empagliflozin Brand 73 $70,304
Farxiga Dapagliflozin Propanediol Brand 32 $33,432
Brilinta Ticagrelor Brand 48 $28,795
Repatha Sureclick Evolocumab Brand 25 $21,333
Ozempic Semaglutide Brand 16 $13,499
Rosuvastatin Calcium Generic 324 $7,583
Metoprolol Succinate Generic 491 $6,253

The 10 drugs with the highest cost, of 52 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 4,694 Part D prescribers listed as Interventional Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 60 billing codes

Paid by Medicare

$386,993

Medicare's payments for the services billed

Medicare patients

1,217

Average age 75

Services billed

5,193

621 women, 596 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 63%
Diabetes 55%
Arthritis 50%
Chronic kidney disease 45%
Heart failure 40%
Atrial fibrillation 35%
COPD 25%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 15 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
LEQVIO
$225 — —
ELIQUIS
$213 381 —
ENTRESTO
$199 183 —
Arcalyst
$174 — —
NEXLETOL
$134 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 15 in the dashboard with a free account

Records

981 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Cardiology in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record